Dr. Melaku Ayalew, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 8439 Lake Mist Way, Fairfax Station, VA 22039 Phone: 703-200-5422 |
News Archive
According to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen) trial patients who received a three-dose induction regimen of Remicade experienced a significantly greater reduction in pain as assessed by four different pain questions after ten weeks, compared with patients who received a single dose of Remicade.
Postpartum depression (PPD) is reported to occur in 10-15% of delivering women with an estimated 400,000 women affected annually in the US. It is the most common complication of childbirth and is a significant public health concern.
Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced that it has received clearance from the U.S. Food and Drug Administration for its IH-1000 blood typing instrument along with approvals for a wide range of associated gel cards and reagents for the U.S. blood typing market.
Treatment that consisted of shock wave (procedure using high-dose ultrasound)-mediated preconditioning of the target heart tissue prior to administration of bone marrow-derived mononuclear cells was associated with significant, albeit modest improvement in left ventricular ejection fraction (a measure of how well the left ventricle of the heart pumps with each contraction) after 4 months in patients with chronic postinfarction heart failure, according to a study in the April 17 issue of JAMA.
› Verified 9 days ago